Join Class Action to Recover Losses from James Hardie Industries plc. (JHX) – Contact Levi & Korsinsky Before December 23, 2025

NEW YORK, NY / ACCESS Newswire / December 22, 2025 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired James Hardie Industries plc. (NYSE:JHX) securities. If you suffered a loss on your James Hardie Industries plc. investment and would like

Class Action Lawsuit Filed Against StubHub Holdings, Inc. (STUB) – Recover Losses – Contact Levi & Korsinsky Before January 23, 2026

NEW YORK, NY / ACCESS Newswire / December 22, 2025 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired StubHub Holdings, Inc. (NYSE:STUB) securities. If you suffered a loss on your StubHub Holdings, Inc. investment and would like to explore

Ongoing Securities Investigation into Coupang, Inc. (CPNG) – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / December 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation into Coupang, Inc. ("Coupang, Inc.") (NYSE:CPNG) concerning potential violations of the federal securities laws. The New York Times published an article on December 10, 2025, entitled "C.E.O. Resigns in Fallout Over Massive South

Securities Class Action Lawsuit Filed Against Inspire Medical Systems, Inc. (INSP) – Levi & Korsinsky Represents Shareholders

NEW YORK, NY / ACCESS Newswire / December 22, 2025 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Inspire Medical Systems, Inc. (NYSE:INSP) securities. If you suffered a loss on your Inspire Medical Systems, Inc. investment and would like

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer

Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients TURKU, FI / ACCESS Newswire / December 22, 2025 / Faron Pharmaceuticals Ltd. (AIM:ARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, today announces the finalization of agreements to initiate the BLAZE

Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB

MALMÖ, SE / ACCESS Newswire / December 22, 2025 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has been appointed In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the members should be one representative of each of

Scroll to Top